Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Net Cash per Share : $13.79 (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Taro Pharmaceutical Industries's Net Cash per Share for the quarter that ended in Dec. 2023 was $13.79.

The historical rank and industry rank for Taro Pharmaceutical Industries's Net Cash per Share or its related term are showing as below:

TARO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.05 Med: 4.95 Max: 15.36
Current: 3.07

During the past 13 years, the highest Price-to-Net-Cash Ratio of Taro Pharmaceutical Industries was 15.36. The lowest was 2.05. And the median was 4.95.

TARO's Price-to-Net-Cash is ranked better than
80.75% of 265 companies
in the Drug Manufacturers industry
Industry Median: 7.76 vs TARO: 3.07

Taro Pharmaceutical Industries Net Cash per Share Historical Data

The historical data trend for Taro Pharmaceutical Industries's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Net Cash per Share Chart

Taro Pharmaceutical Industries Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Cash per Share

Get a 7-Day Free Trial

21.27

22.78

8.45

9.47

11.86

Taro Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															-	11.86	10.90	14.24	13.79

Competitive Comparison of Taro Pharmaceutical Industries's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taro Pharmaceutical Industries's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Price-to-Net-Cash falls into.

Taro Pharmaceutical Industries Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Taro Pharmaceutical Industries's Net Cash per Share for the fiscal year that ended in Mar. 2023 is calculated as

	Net Cash per Share (A: Mar. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(850.289	-	404.654	-	0)	/	37.5846
=	11.86

Taro Pharmaceutical Industries's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(902.216	-	384.086	-	0)	/	37.5846
=	13.79

Taro Pharmaceutical Industries (NYSE:TARO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Taro Pharmaceutical Industries Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

TAL:Germany

Address

14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761

Website

https://www.taro.com

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Executives

Sun Pharma Global Inc	10 percent owner
Sun Pharmaceutical Industries Ltd	10 percent owner, other: Affiliated Party	17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd.	10 percent owner	KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc	10 percent owner	FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403